Nanobiotix updates voting rights and share count

Nanobiotix S.A. reported its share capital and voting rights position as of June 30, 2026, showing 50,825,682 shares outstanding.

Accepted by SEC EDGAR 07/31/2026 - 05:13 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Nanobiotix S.A. reported its share capital and voting rights position as of June 30, 2026, showing 50,825,682 shares outstanding.

The company reported 54,486,890 theoretical voting rights, used as the basis for calculating threshold crossings, and 54,464,772 exercisable voting rights, which exclude shares held in treasury where voting rights are suspended. Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris and listed on Euronext Paris and the Nasdaq Global Select Market.

Key Figures

Shares outstanding: 50,825,682 shares Theoretical voting rights: 54,486,890 voting rights Exercisable voting rights: 54,464,772 voting rights +3 more

6 metrics

Shares outstanding 50,825,682 shares As of June 30, 2026

Theoretical voting rights 54,486,890 voting rights Gross voting rights as of June 30, 2026

Exercisable voting rights 54,464,772 voting rights Net voting rights as of June 30, 2026

Patent families More than 30 Patent families across three nanotechnology platforms

Nanotechnology platforms 3 platforms Applications in oncology, bioavailability and biodistribution, CNS disorders

Year of incorporation 2003 Year Nanobiotix was incorporated

Key Terms

theoretical voting rights, exercisable voting rights, threshold crossings, treasury, +1 more

5 terms

theoretical voting rights financial

"The total number of theoretical (or “gross”) voting rights is used"

Theoretical voting rights are the share of control an investor would have if all possible sources of additional shares—such as stock options, warrants and convertible bonds—were turned into ordinary shares. Investors care because this “what-if” number shows potential dilution of current owners and the maximum voting power others could gain, helping assess control risk and how future actions might change company decisions, like a snapshot of ownership if every coupon were cashed in.

exercisable voting rights financial

"The total number of exercisable at a shareholders’ meeting (or “net”) voting rights"

Exercisable voting rights are the actual, usable votes attached to a security or position that allow the holder to influence company decisions at shareholder meetings—for example electing the board or approving mergers. They matter to investors because the number of votes someone can cast determines who controls the company and its strategy, similar to having usable tickets at a town meeting rather than placeholders, and can affect share value, takeover risk and how much influence minority holders have.

threshold crossings financial

"used as the basis for calculating threshold crossings"

treasury financial

"without taking into account shares for which voting rights have been suspended as shares held in treasury"

The treasury is the department or area within a government or organization responsible for managing its money, finances, and financial strategies. It handles tasks like collecting revenue, paying bills, and planning for future financial needs, much like a household manages its budget. For investors, understanding the treasury is important because it influences interest rates, government spending, and overall economic stability.

nanotechnology platforms technical

"associated with three (3) nanotechnology platforms with applications in 1) oncology"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share capital did Nanobiotix (NBTX) report as of June 30, 2026?

Nanobiotix reported 50,825,682 shares outstanding as of June 30, 2026. This figure reflects the total number of issued shares forming the company’s share capital at that date on Euronext Paris and Nasdaq.

How many voting rights does Nanobiotix (NBTX) have on a theoretical basis?

Nanobiotix reported 54,486,890 theoretical voting rights as of June 30, 2026. This gross figure includes all shares with attached voting rights, even those where voting rights are suspended, and is used to calculate regulatory threshold crossings.

What are Nanobiotix (NBTX) exercisable voting rights as of June 30, 2026?

Exercisable voting rights totaled 54,464,772 as of June 30, 2026. This net number excludes treasury shares for which voting rights are suspended and represents voting rights that can actually be exercised at a shareholders’ meeting.

On which markets is Nanobiotix (NBTX) listed?

Nanobiotix is listed on Euronext Paris and the Nasdaq Global Select Market. The company has been listed in Paris since 2012 and on Nasdaq in New York City since December 2020, giving it access to European and U.S. capital markets.

What kind of company is Nanobiotix (NBTX) and where is it based?

Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France. Incorporated in 2003, it develops physics-based therapeutic approaches and holds more than 30 patent families across three nanotechnology platforms, including applications in oncology.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On July 30, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated July 30, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: July 30, 2026		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

EXHIBIT 99.1

Voting Rights and Shares Capital of the Company

PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

Paris, France, July 30, 2026
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
June 30, 2026	50,825,682	54,486,890	54,464,772

***

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has a subsidiary in Cambridge, Massachusetts (United States).

Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

¹ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.

Attachments

• 2026-07-30 -- NBTX -- Voting Rights & Shares Capital -- FINAL (https://ml.globenewswire.com/Resource/Download/797c58de-7a9a-478e-8163-f9b2827b60fd)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 7.6 KB